Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Marine natural product shows promise for hyperproliferative and inflammatory conditions

Oct. 10, 2000

Positive effects of PARP inhibitor in animal model of acute inflammation

Oct. 10, 2000

Advanced Biotherapy's anti-interferon gamma drug shows promise in the clinic

Oct. 10, 2000

Analgesic activity of S-19812 assessed in rodent models and reported at OARSI meeting

Oct. 9, 2000

Coulter obtains rights to technology related to RA treatment

Oct. 5, 2000

Japanese lab presents new inhibitors of TNF production

Oct. 4, 2000

Novartis reports success in developing orally active dual MMP/TNF-alpha inhibitors

Oct. 3, 2000

New class of oral TNF-alpha synthesis inhibitors presented at September conference

Oct. 3, 2000

Two new patents cover VCAM-1/VLA-4 inhibitors from Roche and their use

Oct. 2, 2000

Selective COX-2 inhibitor with promising profile emerges from Abbott R&D

Oct. 2, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...